PUREVAX ® is unique :

• The only non-adjuvanted feline vaccine range and the only range that comes in a 0.5 ml dose *

• The only vaccine range ever awarded International Society of Feline Medicine ‘ Easy to Give ’ accreditation *

• The only FeLV vaccine licensed for annual use , meeting the current WSAVA Guidelines 1

• A range enabling vaccination tailored to the cat

• Supported by a unique support and education package to help you communicate with clients

* PUREVAX ® Rabies remains in 1 ml and is excluded from ISFM Easy to Give accreditation .

1 Squires RA , Crawford C , Marcondes M , Whitley N . 2024 guidelines for the vaccination of dogs and cats – compiled by the Vaccination Guidelines Group ( VGG ) of the World Small Animal Veterinary Association ( WSAVA ). J Small Anim Pr 2024 ; 65:277 – 316 . https :// doi . org / 10.1111 / jsap . 13718

PUREVAX ® FeLV contains feline leukaemia virus recombinant canarypox virus ( vCP97 ). PUREVAX ® Rabies contains rabies recombinant canarypox virus ( vCP65 ). PUREVAX ® RC contains attenuated feline rhinotracheitis herpesvirus ( FHV F2 strain ) and inactivated feline calicivirus antigens ( FCV 431 and G1 strains ). PUREVAX ® RCP contains attenuated feline rhinotracheitis herpesvirus ( FHV F2 strain ), inactivated feline calicivirus antigens ( FCV 431 and G1 strains ) and attenuated feline panleucopenia virus ( PLI IV ). PUREVAX ® RCP FeLV contains attenuated feline rhinotracheitis herpesvirus ( FHV F2 strain ), inactivated feline calicivirus antigens ( FCV 431 and G1 strains ), attenuated feline panleucopenia virus ( PLI IV ) and FeLV recombinant canarypox virus ( vCP97 ). PUREVAX ® RCPCh contains attenuated feline rhinotracheitis herpesvirus ( FHV F2 strain ), inactivated feline calicivirus antigens ( FCV 431 and G1 strains ), attenuated Chlamydophila felis ( 905 strain ) and attenuated feline panleucopenia virus ( PLI IV ). PUREVAX ® RCPCh FeLV contains attenuated feline rhinotracheitis herpesvirus ( FHV F2 strain ), inactivated feline calicivirus antigens ( FCV 431 and G1 strains ), attenuated Chlamydophila felis ( 905 strain ), attenuated feline panleucopenia virus ( PLI IV ) and FeLV recombinant canarypox virus ( vCP97 ). PUREVAX ® FeLV suspension for injection is indicated for active immunisation of cats of 8 weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease . PUREVAX ® Rabies suspension for injection is indicated for active immunisation of cats 12 weeks of age and older to prevent mortality due to rabies infection . PUREVAX ® RC lyophilisate and solvent for suspension for injection is indicated for active immunisation of cats aged 8 weeks and older : against feline viral rhinotracheitis to reduce clinical signs ; and against calicivirus infection to reduce clinical signs . PUREVAX ® RCP lyophilisate and solvent for suspension for injection is indicated for active immunisation of cats aged 8 weeks and older ; against feline viral rhinotracheitis to reduce clinical signs ; against calicivirus infection to reduce clinical signs ; and against feline panleucopenia to prevent mortality and clinical signs . PUREVAX ® RCP FeLV lyophilisate and solvent for suspension for injection is indicated for active immunisation of cats aged 8 weeks and older : against feline viral rhinotracheitis to reduce clinical signs ; against calicivirus infection to reduce clinical signs ; against feline panleucopenia to prevent mortality and clinical signs ; and against leukaemia to prevent persistent viraemia and clinical signs of the related disease . PUREVAX ® RCPCh lyophilisate and solvent for suspension for injection is indicated for active immunisation of cats aged 8 weeks and older : against feline viral rhinotracheitis to reduce clinical signs , against calicivirus infection to reduce clinical signs , against Chlamydophila felis infection to reduce clinical signs and against feline panleukopenia to prevent mortality and clinical signs . PUREVAX ® RCPCh FeLV lyophilisate and solvent for suspension for injection is indicated for active immunisation of cats aged 8 weeks and older : against feline viral rhinotracheitis to reduce clinical signs ; against calicivirus infection to reduce clinical signs ; against Chlamydophila felis infection to reduce clinical signs ; against feline panleucopenia to prevent mortality and clinical signs ; and against leukaemia to prevent persistent viraemia and clinical signs of the related disease . UK : POM-V . For information about side effects , precautions , warnings and contraindications please refer to the product packaging and package leaflet . Prescription decisions are for the person issuing the prescription alone . Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd , RG12 8YS , UK . UK Tel : 01344 746959 ( sales ) or 01344 746957 ( all queries ). Email : vetenquiries @ boehringer-ingelheim . com . PUREVAX

14 ® is a registered trademark of Boehringer Ingelheim Animal Health France SCS , used under licence . © 2025 Boehringer Ingelheim Animal Health UK Ltd . All rights reserved .

Veterinary Nursing Journal

Date of preparation : Feb 2025 . UI-PET-0012-2025 . Use Medicines Responsibly .